Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Rigetti Computing Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.06 (market cap $39.89B), while Rigetti Computing Inc trades at $15.45 (market cap $5.50B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.3× Rigetti Computing Inc's market cap. Which is the better fit depends on your goals.
| ALNY | RGTI | |
|---|---|---|
Market Cap | $39.89B | $5.50B |
Sector | Health | Technology |
52-Week High | $491.22 | $56.34 |
52-Week Low | $278.09 | $12.18 |
Enterprise Value | $38.15B | $5.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $288.06, down 3.58% today, with a bullish technical signal supported by oscillators and strong institutional sentiment. The company reported robust revenue growth to $3.71B in 2025, turning profitable with net income of $313.75M, and shows a positive earnings beat trend. Recent news highlights pipeline advancements and strategic AI partnerships aimed at accelerating drug discovery.
Outlook remains positive with a consensus price target of $414.40, implying 44% upside, driven by pipeline diversification and market expansion. Key risks include clinical trial outcomes and dependence on key drug Amvuttra. Wall Street maintains strong buy consensus (75% buy ratings) amid expectations for sustained growth and potential S&P 500 inclusion.
Rigetti Computing trades at $16.54, down 2.65% for the day, with technical indicators showing a bearish trend despite oversold RSI readings. The company reported $7.09M in revenue for 2025 but posted a net loss of $216.21M, reflecting negative profit margins. Recent news highlights its infrastructure developments and government funding potential, while the stock faces sector-wide volatility in quantum computing.
Wall Street maintains a bullish outlook with 85.7% buy ratings and a $32.67 consensus price target, signaling significant upside. However, high cash burn, speculative technology timeline, and intense competition pose substantial risks. Investment appeal hinges on long-term quantum advantage realization versus near-term financial sustainability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
